Rash generally manifests as a mild or moderate erythematous and acneiform rash, which may occur or worsen in areas exposed to the sun.1
Bullous, blistering and exfoliative skin conditions have also been reported, including rare cases suggestive of Stevens-Johnson syndrome and toxic epidermal necrolysis.1 GIOTRIF® (afatinib) treatment should be interrupted or discontinued if the patient develops any severe bullous, blistering or exfoliating conditions.1
Grade 3–4 or prolonged* or intolerable Grade 2:
Adapted from CTCAE version 3.4
AE=adverse event, SPF=sun protection factor, UVA=ultraviolet A, UVB=ultraviolet B, CTCAE=Common Terminology Criteria for Adverse Events
You're now leaving our website...
Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.
Click here for general international information about afatinib for non-small-cell lung cancer treatment.